News & events

Press Releases

On the 28th March 2022, OncoArendi changed its name to Molecure

Molecure announces first patient dosed in Phase I trial with novel, first-in-class dual arginase inhibitor OATD-02 for the treatment of cancer

8 March 2023

Molecure Appoints Dr. Samson Fung, Chief Medical Officer to its Management Board as it Continues to Focus on Successfully Progressing its Expanded Clinical Portfolio Copy

23 January 2023

R&D Day Presentation, 07.12.2022

7 December 2022

Molecure Announces Details for Virtual R&D Day Webcast to be held on Wednesday 7th December 2022

5 December 2022

Molecure to begin clinical development of novel dual arginase inhibitor OATD-02 for the treatment of cancer after gaining permission to conduct first clinical trial in Poland

28 November 2022

Molecure to Host Virtual R&D Day on 7th December 2022

14 November 2022

Events & Presentations

ESMO – 8-12 September 2017 Madrid

1 September 2017

ERS – 9-13 September 2017 Milan

1 September 2017

BIO USA – San Diego 19-22 June 2017

1 June 2017

ATS – Washington 19-24 May 2017

1 May 2017